Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial

@inproceedings{Howard2018AntipsychoticTO,
  title={Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial},
  author={Robert J. Howard and Elizabeth Cort and Robert K. Bradley and Emma Amanda Harper and Linda Elizabeth Kelly and Peter Bentham and Craig William Ritchie and Suzanne J. Reeves and Waleed Fawzi and Gill Livingston and Andrew Sommerlad and Sabu K. Oomman and Ejaz Nazir and Ramin Nilforooshan and Robert Barber and Chris Fox and Ajay Verma Macharouthu and Pranathi Ramachandra and Vivek Pattan and John D. Sykes and Val Curran and C Katona and Tom Dening and Martin Knapp and Richard Gray},
  booktitle={The lancet. Psychiatry},
  year={2018}
}
BACKGROUND Very late (aged ≥60 years) onset schizophrenia-like psychosis occurs frequently but no placebo-controlled, randomised trials have assessed the efficacy and risks of antipsychotic treatment. We investigated whether low-dose amisulpride (100 mg daily) is superior to placebo in reducing psychosis symptoms over 12 weeks and whether any benefit is maintained by continuing treatment after 12 weeks. METHODS The ATLAS double-blind controlled trial enrolled participants from 25 old age… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES